Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Mechanical respiratory support in cardiogenic shock: reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Pulmonary artery pulsatility index: physiological basis and clinical application

    Research output: Contribution to journalReviewResearchpeer-review

  3. Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Associations between blood cultures after surgery for colorectal cancer and long-term oncological outcomes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Evaluation of computed tomography myocardial perfusion in women with angina and no obstructive coronary artery disease

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.

METHODS AND RESULTS: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).

CONCLUSION: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

Original languageEnglish
JournalEuropean Journal of Heart Failure
Volume19
Issue number1
Pages (from-to)69-77
ISSN1388-9842
DOIs
Publication statusPublished - 2017

ID: 49154599